Hypereosinophilic syndrome: An update

American Journal of Hematology

Volumn 80, Issue 2, 2005, Pages 148-157

  Wilkins, H Jeffrey ^a   Crane, Martin M ^a   Copeland, Kelly ^a   Williams, William V ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

Cytokines; Eosinophils; Hypereosinophilic syndrome; Pathophysiology; Treatment

Indexed keywords

ALPHA INTERFERON; BIOLOGICAL RESPONSE MODIFIER; BUSULFAN; CHLORAMBUCIL; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTOKINE; CYTOTOXIC AGENT; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYDROXYUREA; IMATINIB; INTERLEUKIN 3; INTERLEUKIN 5; MEPOLIZUMAB; METHOTREXATE; MONOCLONAL ANTIBODY; PREDNISONE; PROTEIN TYROSINE KINASE INHIBITOR; VINCRISTINE;

ALOPECIA; ANEMIA; ANXIETY DISORDER; ARTHRALGIA; BODY WEIGHT DISORDER; BONE MARROW SUPPRESSION; CARDIOTOXICITY; CATARACT; CENTRAL NERVOUS SYSTEM DISEASE; CONVULSION; CORTICOSTEROID INDUCED OSTEOPOROSIS; CUSHINGOID SYNDROME; DEPRESSION; DIABETES MELLITUS; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; EDEMA; EOSINOPHIL; EOSINOPHILIA; FATALITY; FATIGUE; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; GROWTH RETARDATION; HEADACHE; HUMAN; HYPEREOSINOPHILIC SYNDROME; HYPERTENSION; IMMUNOREGULATION; INSOMNIA; IRRITABILITY; LEUKOPENIA; LIVER DYSFUNCTION; LIVER TOXICITY; MUSCLE CRAMP; MYALGIA; MYELODYSPLASIA; MYOPATHY; NAUSEA; NEPHROTOXICITY; NERVOUSNESS; PARESTHESIA; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RARE DISEASE; RASH; REVIEW; SIDE EFFECT; SURVIVAL; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREMOR; VOMITING;

ADRENAL CORTEX HORMONES; ANTINEOPLASTIC AGENTS; BIOLOGICAL RESPONSE MODIFIERS; CYTOKINES; GENE EXPRESSION REGULATION; HUMANS; HYPEREOSINOPHILIC SYNDROME;

EID: 26444539893     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/ajh.20423     Document Type: Review

References (47)

1. Hardy WR, Anderson RE. The hypereosinophilic syndromes. Ann Intern Med 1968;68(6):1220-1229.
2. Fauci AS, Harley JB, Roberts WC, et al. NIH conference. The idiopathic hypereosinophilic syndrome. Clinical, pathophysiologic, and therapeutic considerations. Ann Intern Med 1982;97(1):78-92.
3. Weller PF, Bubley GJ. The idiopathic hypereosinophilic syndrome. Blood 1994;83(10):2759-2779.
4. Roufosse F, Cogan E, Goldman M. The hypereosinophilic syndrome revisited. Annu Rev Med 2003;54:169-184.
5. Chusid MJ, Dale DC, West BC, Wolff SM. The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature. Medicine (Baltimore) 1975;54(1):1-27.
6. Lefebvre C, Bletry O, Degoulet P, et al. Prognostic factors of hypereosinophilic syndrome. Study of 40 cases. Ann Med Interne (Paris) 1989;140(4):253-257.
7. Bain BJ. Hypereosinophilia. Curr Opin Hematol 2000;7(1):21-25.
8. Spry CJF. Idiopathic hypereosinophilic syndrome. In: Makino S, Fukuda T, editors. Eosinophils: biological and clinical aspects. Boca Raton, FL: CRC; 1993. p 403-419.
9. Roufosse F, Bartholome E, Schandene L, et al. The idiopathic hypereosinophilic syndrome: clinical presentation, pathogenesis and therapeutic strategies. Drugs Today (Barc) 1998;34(4):361-373.
10. Simon HU, Plotz SG, Dummer R, Blaser K. Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia. N Engl J Med 1999;341(15):1112-1120.
11. Assa'ad AH, Spicer RL, Nelson DP, Zimmermann N, Rothenberg ME. Hypereosinophilic syndromes. Chem Immunol 2000;76:208-209.
12. SEER Cancer Statistics Review, 1975-2001. Retrieved 4 August 2004 from http://seer.cancer.gov/csr/1975_2001/
13. Spry CJ, Davies J, Tar PC, et al. Clinical features of fifteen patients with the hypereosinophilic syndrome. Q J Med 1983;52(205):1-22.
14. Chaiken IM, Williams WV. Identifying structure-function relationships in four-helix bundle cytokines: towards de novo mimetics design. Trends Biotechnol 1996;14(10):369-375.
15. Wong CK, Ip WK, Lam CW. Biochemical assessment of intracellular signal transduction pathways in eosinophils: implications for pharmacotherapy. Crit Rev Clin Lab Sci 2004;41(1):79-113.
16. Sanderson CJ. Interleukin-5, eosinophils, and disease. Blood 1992;79(12):3101-3109.
17. Wardlaw AJ. Eosinophils in the 1990s: new perspectives on their role in health and disease. Postgrad Med J 1994;70(826):536-552.
18. Gleich GJ. Mechanisms of eosinophil-associated inflammation. J Allergy Clin Immunol 2000;105(4):651-663.
19. Gleich GJ, Schroeter AL, Marcoux JP, et al. Episodic angioedema associated with eosinophilia. N Engl J Med 1984;310(25):1621-1626.
20. Butterfreld JH, Leiferman KM, Gleich GJ. Nodules, eosinophilia, rheumatism, dermatitis and swelling (NERDS): a novel eosinophilic disorder. Clin Exp Allergy 1993;23(7):571-580.
21. Rothenberg ME. Eosinophilic gastrointestinal disorders (EGID). J Allergy Clin Immunol 2004;113(1):11-28; quiz 29.
22. Parrillo JE, Fauci AS, Wolff SM. Therapy of the hypereosinophilic syndrome. Ann Intern Med 1978;89(2):167-172.
23. Yoon TY, Ahn GB, Chang SH. Complete remission of hypereosinophilic syndrome after interferon-alpha therapy: report of a case and literature review. J Dermatol 2000;27(2):110-115.
24. Schooley RT, Flaum MA, Gralnick HR, Fauci AS. A clinicopathologic correlation of the idiopathic hypereosinophilic syndrome. II. Clinical manifestations. Blood 1981;58(5):1021-1026.
25. Butterfreld JH, Gleich GJ. Interferon-alpha treatment of six patients with the idiopathic hypereosinophilic syndrome. Ann Intern Med 1994;121(9):648-653.
26. Baratta L, Afeltra A, Delfino M, et al. Favorable response to high-dose interferon-alpha in idiopathic hypereosinophilic syndrome with restrictive cardiomyopathy-case report and literature review. Angiology 2002;53(4):465-470.
27. Zabel P, Schlaak M. Cyclosporin for hypereosinophilic syndrome. Ann Hematol 1991;62(6):230-231.
28. Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001;344(14):1038-1042.
29. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344(14):1031-1037.
30. Ault P, Cortes J, Koller C, et al. Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate. Leuk Res 2002;26(9):881-884.
31. Cools J, DeAngelo DJ, Gotlib J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003;348(13):1201-1214.
32. Gleich GJ, Leiferman KM, Pardanani A, Tefferi A, Butterfreld JH. Treatment of hypereosinophilic syndrome with imatinib mesilate. Lancet 2002;359(9317):1577-1578.
33. Klion AD, Noel P, Akin C, et al. Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. Blood 2003;101(12):4660-4666.
34. Klion AD, Robyn J, Akin C, et al. Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome. Blood 2004;103(2):473-478.
35. Pardanani A, Reeder T, Porrata LF, et al. Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders. Blood 2003;101(9):3391-3397.
36. rd, Schrier SL, Gilliland DG, Coutre SE. The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management. Blood 2004;103(8):2879-2891.
37. Leiferman KM, Gleich GJ. Hypereosinophilic syndrome: case presentation and update. J Allergy Clin Immunol 2004;113(1):50-58.
38. Bain B, Pierre R, Imbert M, et al. Chronic eosinophilic leukaemia and the hypereosinophilic syndrome. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. World Health Organization classification of tumours: pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon, France: IARC Press; 2001. p 29-31.
39. Gleevec [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corp.; 2003.
40. Buttner C, Lun A, Splettstoesser T, et al. Monoclonal antiinterleukin-5 treatment suppresses eosinophil but not T-cell functions. Eur Respir J 2003;21(5):799-803.
41. Gnanakumaran G, Babu KS. Technology evaluation: mepolizumab, GlaxoSmithKline. Curr Opin Mol Ther 2003;5(3):321-325.
42. Menzies-Gow A, Flood-Page P, Sehmi R, et al. Anti-IL-5 (mepolizumab) therapy induces bone marrow eosinophil maturational arrest and decreases eosinophil progenitors in the bronchial mucosa of atopic asthmatics. J Allergy Clin Immunol 2003;111(4):714-719.
43. Garrett JK, Jameson SC, Thomson B, et al. Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes. J Allergy Clin Immunol 2004;113(1):115-119.
44. Koury MJ, Newman JH, Murray JJ. Reversal of hypereosinophilic syndrome and lymphomatoid papulosis with mepolizumab and imatinib. Am J Med 2003;115(7):587-589.
45. Plotz SG, Simon HU, Darsow U, et al. Use of an anti-interleukin-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis. N Engl J Med 2003;349(24):2334-2339.
46. Data on file. King of Prussia, PA; GlaxoSmithKline; 2003.
47. Klion AD, Law MA, Noel P, et al. Safety and efficacy of the monoclonal anti-interleukin-5 antibody SCH55700 in the treatment of patients with hypereosinophilic syndrome. Blood 2004;103(8):2939-2941.